| Similar Articles |
|---|
 |
The Motley Fool
November 21, 2011
David Williamson |
Market Volatility = Biotech Opportunity Gilead buys Pharmasset, Spectrum gets a break, and Eylea's approved.   |
The Motley Fool
November 16, 2011
David Williamson |
3 Biotechs Beating the Market The daily health-care news investors need to read. |
The Motley Fool
January 9, 2012
David Williamson |
Inhibitex Is an Instant Double Some takeout rumors do come true. |
The Motley Fool
November 21, 2011
David Williamson |
Pharmasset Acquired, Shares Jump 85% Gilead Sciences buys Pharmasset and hepatitis C drug PSI-7977. |
The Motley Fool
December 14, 2011
David Williamson |
BioSante Investors: It Was Nice While It Lasted Libigel loses to placebo in two studies, shares down 75% after hours. |
The Motley Fool
December 15, 2011
David Williamson |
1 Massive Biotech Bloodbath Trial results and FDA panels ruled the health-care sector today. |
The Motley Fool
November 30, 2011
Brian Orelli |
Up Big With Room to Run Lofty hep C valuations are par for the course. |
The Motley Fool
January 10, 2012
Sean Williams |
Idenix Pharmaceuticals Shares Skyrocketed Again: What You Need to Know Shares of hepatitis-C drug hopeful Idenix Pharmaceuticals are continuing their rally for a second day, currently up 21%, as speculation swirls that it will be the next takeover candidate. |
The Motley Fool
January 9, 2012
David Williamson |
4 Stocks Dominating the Dow These stocks were today's biggest gainers. |
The Motley Fool
November 7, 2011
David Williamson |
Health-Care News You Can't Afford to Miss Highlighting the day's health-care stories: FDA approval for Johnson & Johnson... Inhibitex kept its streak of double-digit gains alive with another 14% surge today... 13% plunge for Optimer Pharmaceuticals... |
The Motley Fool
November 5, 2011
David Williamson |
Inhibitex Investors: Why Shares Popped 115% Great results for INX-189 send shares skyward. |
The Motley Fool
January 13, 2012
Sean Williams |
CEO Gaffe of the Week: Bristol-Myers Squibb Some days, CEOs would be better off staying in bed. |
The Motley Fool
December 16, 2011
Brian Orelli |
Safety (Still) Trumps Acquisitions in Hep C Pharmasset announced it was discontinuing all treatment arms in one of its phase 2b trials that contain the drug PSI-938. The drug candidate caused laboratory abnormalities in tests associated with liver function. |
The Motley Fool
January 17, 2008
Brian Lawler |
The Good Times Roll for Pharmasset Shares ride high after the company releases positive clinical trial data. |
The Motley Fool
January 9, 2012
Brian Orelli |
3 Reasons Hep C Premiums Might Not Last Careful what you wish for. |
The Motley Fool
December 15, 2011
Anders Bylund |
BioSante Pharmaceuticals' Shares Died: What You Need to Know Is this meaningful, or just another movement for BioSante Pharmaceuticals? |
The Motley Fool
November 4, 2011
Brian Orelli |
You Should Have Seen These Biotech Failures Coming Micro cap biotechs are a value for a reason. |
The Motley Fool
June 14, 2011
Brian Orelli |
Going for Seconds in the Hepatitis C Space Fresh from the Food and Drug Administration's approval of its hepatitis C drug, Incivek, Vertex has licensed a pair of hepatitis C compounds from privately held Alios BioPharma. |
The Motley Fool
November 29, 2011
Brian Orelli |
Every Biotech Is for Sale It just depends on the right price. |
The Motley Fool
December 21, 2011
Brian Orelli |
Knocked Down? Not for Long! Last week shares of Antares Pharma got knocked down after BioSante Pharmaceuticals' LibiGel didn't live up to expectations. |
The Motley Fool
October 3, 2011
Brian Richards |
With 9 Months Down, These Are the Best Stocks of 2011 A look at the top-performing stocks of the year (so far). |
The Motley Fool
March 11, 2010
Jim Mueller |
Is Medivation a Buy? What is the thinking with regards to Medivation today? It already got a big haircut last week. Is it worth investing in at these lower prices? |
The Motley Fool
September 11, 2007
Brian Lawler |
Score One for Pharmasset Shares of Pharmasset were up after the company announced impressive results for its Hepatitis C virus drug candidate R7128. Investors should continue to watch closely. |
Chemistry World
January 11, 2012
Andrew Turley |
BMS spends $2.5 billion on antiviral firm The move will stock Bristol-Myers Squibb's pipeline with antivirals, most notably INX-189, a nucleotide polymerase inhibitor which is in Phase II trials for treating hepatitis C virus infection. |
The Motley Fool
May 31, 2011
Brian Orelli |
5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals. |
The Motley Fool
July 7, 2011
Brian Orelli |
J&J's Been Busy Johnson & Johnson announced it was hooking up with another partner, Pharmasset, to create a hepatitis C drug combo. |
The Motley Fool
January 9, 2012
Travis Hoium |
Idenix Pharmaceuticals Shares Jumped: What You Need to Know Shares of Idenix Pharmaceuticals got a positive diagnosis today and climbed 43% after the company released positive data for its hepatitis C drug. |
The Motley Fool
July 13, 2011
David Williamson |
Roundtable: The Biggest Risks in Biotech Three biotech companies to steer clear of. |
The Motley Fool
July 27, 2010
Jim Mueller |
3 Stocks to Play Biotech Here are three promising ideas for this exciting area. |
The Motley Fool
January 9, 2012
Dan Caplinger |
What's Moving the Dow Today A brief look at the market's moves so far on Monday. |
The Motley Fool
December 15, 2011
Brian Orelli |
BioSante Shares Crushed by Placebo Effect BioSante's LibiGel efficacy is not deemed statistically significant. |
The Motley Fool
November 22, 2011
Brian Orelli |
This Spec Pharma Hopes Convenience Trumps All Spectrum Pharmaceuticals' Zevalin no longer requires a bioscan. |
The Motley Fool
August 29, 2011
Anders Bylund |
Idenix Pharmaceuticals' Shares Popped: What You Need to Know Shares of viral-disease medication developer Idenix Pharmaceuticals climbed 10.9% on vanishingly thin trading volume. |
The Motley Fool
April 29, 2008
Brian Lawler |
So Pharmasset, So Good Early data hints at a promising hepatitis C treatment. |
The Motley Fool
November 3, 2011
David Williamson |
Medivation Investors: Why Your Stock Just Jumped 140% Medivation shares pop on trial success for prostate cancer treatment MDV3100. |
The Motley Fool
May 12, 2010
Matt Koppenheffer |
Are Health-Care Stocks a Buy? Health-care stocks have underperformed the market so far this year. Is it time for a turnaround? |
Pharmaceutical Executive
December 1, 2011
Ben Comer |
Pharm Exec's 2012 Pipeline Report It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle? |
The Motley Fool
September 30, 2011
David Williamson |
This Week in Biotech Biotech news about Array BioPharma, Human Genome Sciences, Pharmasset, and more. |
The Motley Fool
October 24, 2007
Brian Lawler |
Pharmasset on the Fast Track Hepatitis and HIV drug developer announced that its lead antihepatitis C compound has received fast-track status from the FDA. The decision is not fantastic news, but it could help. Investors, take note. |
